/

VCYT

Veracyte, Inc.Pre-market

44.02−1.21 −2.68%USD

NasdaqGM · as of Oct 12, 16:00 ET · 15m delayPre-market 44.29 +0.61%

Open

45.18

Prev close

45.23

Day range

43.2945.22

52-week range

29.4660.91

Volume

1.15M0.84×

Mkt cap

3.54B

P/E ttm

31.44

Fwd P/E

22.63

EPS ttm

1.40

Div yield

0.00%

Earnings

Jul 30, 2026

From 52w high

−27.73%

Price Chart

Yahoo Finance · delayed

VCYTOct 12, 2026O 45.18H 45.22L 43.29C 44.02−1.21 (−2.68%)Vol 1.15M

SMA 5043.72
SMA 20042.57

1Y change +26.49% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

VCYT Veracyte, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −7.66%
1 month: +7.71%
3 months: −23.42%
6 months: +35.70%
Year to date: +4.56%
1 year: +26.49%

Valuation & ownership

Market cap: 3.54B
Enterprise value: 3.09B
P/E (ttm): 31.44
Forward P/E: 22.63
PEG ratio: —
Price / book: 2.55
Price / sales (ttm): 6.30
EV / EBITDA: 27.25
EPS (ttm): 1.40
EPS (forward): 1.95
Beta (5y monthly): 1.95
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 80.39M
Float: 79.88M
Short % of float: 14.96%
Short ratio (days): 7.05
Held by insiders: 0.49%
Held by institutions: 114.79%
Avg volume (3m): 1.36M
50-day average: 43.72
200-day average: 42.57
52-week change: +26.49%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 49.1
vs 50-day SMA: +0.69%
vs 200-day SMA: +3.41%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▲ above
ATR (14) % of price: 5.76%
Realised vol (20d, ann.): 69.6%
From 52-week high: −27.73%
From 52-week low: +49.45%

ANR

Analyst Consensus

12 analysts

Consensus

Buy

1.62 on a 1 (strong buy) – 5 (sell) scale

Mean target

58.42

+32.70% implied

Low 44.00Median 59.00High 70.00

Recommendation trend

Now11 / 1 / 1
1m ago

DES

About Veracyte, Inc.

Yahoo Finance profile

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Sector: Healthcare
Industry: Diagnostics & Research
Employees: 755
Headquarters: South San Francisco, CA, United States
Website: veracyte.com
Officers: Mr. Marc A. Stapley CEO & Director
Ms. Rebecca Chambers Executive VP & CFO
Dr. Phillip G. Febbo M.D. Chief Scientific & Medical Officer
Ms. Annie McGuire Executive VP, General Counsel & Head of Market Access

SEAS

Seasonality · VCYT

2013–2026 · monthly returns

Strongest month Nov +11.69%Weakest month Sep −6.93%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-9.5	-3.9	-12.0	2.2	40.8	26.7	-21.1	-6.8	6.6	-4.4			+4.6%
2025	14.8	-23.6	-14.7	2.9	-12.8	1.6	-13.0	29.1	13.2	5.1	31.2	-11.1	+6.3%
2024	-9.1	-5.9	-5.9	-11.7	6.0	4.4	10.8	31.5	7.9	-0.9	27.3	-7.8	+43.9%
2023	5.9	-2.1	-9.4	1.5	14.3	-1.6	7.8	-3.8	-15.4	-7.2	23.6	7.5	+15.9%
2022	-26.2	-8.6	-0.8	-25.8	-14.1	13.2	32.4	-22.6	-18.6	21.1	37.9	-14.5	−42.4%
2021	15.9	2.4	-7.4	-7.4	-21.5	2.4	11.5	8.0	-3.5	3.1	-13.4	-0.7	−15.8%
2020	-6.0	-5.9	-1.5	10.9	-7.5	3.8	37.7	-6.6	-2.5	6.7	57.3	-10.2	+75.3%
2019	44.6	11.1	23.8	-8.6	-0.9	25.8	-0.5	-6.6	-9.4	-4.5	25.3	-2.8	+121.9%
2018	-2.1	-5.8	-7.6	9.0	26.2	22.1	16.0	16.7	-24.4	55.5	-17.6	2.8	+92.6%
2017	-4.7	5.0	18.5	-7.7	-3.9	2.3	-4.0	2.4	7.1	-2.5	-20.7	-3.7	−15.6%
2016	-10.0	1.9	-18.2	7.4	-5.3	-8.4	-1.6	13.7	35.2	-4.6	5.1	1.4	+7.5%
2015	-16.1	8.5	-17.2	25.7	14.8	6.1	4.1	-18.7	-50.3	38.8	10.4	0.1	−25.5%
2014	1.0	9.3	7.0	-25.2	18.8	12.5	-16.5	-12.2	-22.4	-17.2	-19.2	48.2	−33.4%
2013											4.8	11.7	+17.0%

INSD

Insider Activity · VCYT

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

248.4K shares

Sells, 6 months

237.6K shares

Net shares

+10.9K

Net change in insider shares

+2.80%

Date	Insider	Transaction	Shares	Value
Sep 20, 2026	Leite JohnOfficer	Sale at price 40.00 per share.	4K	$160.60K
Sep 13, 2026	Holstein JensDirector	Sale at price 40.95 per share.	5K	$204.75K
Sep 3, 2026	Chambers RebeccaChief Financial Officer	Sale at price 42.81 - 43.71 per share.	3.7K	$157.39K
Sep 3, 2026	Mcguire AnnieGeneral Counsel	Sale at price 42.79 - 43.67 per share.	3.3K	$140.21K
Sep 3, 2026	Febbo Phillip GOfficer	Sale at price 42.89 - 43.66 per share.	13.1K	$564.41K
Aug 31, 2026	Bhanji MunaDirector	Sale at price 42.97 per share.	1.9K	$80.10K
Jun 17, 2026	Eastham KarinDirector	Sale at price 52.78 - 53.55 per share.	3.7K	$197.23K
Jun 10, 2026	Holstein JensDirector	Stock Award(Grant) at price 0.00 per share.	5.3K	—
Jun 10, 2026	Bhanji MunaDirector	Stock Award(Grant) at price 0.00 per share.	5.3K	—
Jun 10, 2026	Barr EliavDirector	Stock Award(Grant) at price 0.00 per share.	5.3K	—
Jun 10, 2026	Miller Thomas FDirector	Stock Award(Grant) at price 0.00 per share.	5.3K	—
Jun 10, 2026	Shafer David BrentDirector	Stock Award(Grant) at price 0.00 per share.	5.3K	—
Jun 10, 2026	Eastham KarinDirector	Stock Award(Grant) at price 0.00 per share.	5.3K	—
Jun 10, 2026	Jones EvanDirector	Stock Award(Grant) at price 0.00 per share.	5.3K	—
Jun 10, 2026	Epstein Robert SDirector	Stock Award(Grant) at price 0.00 per share.	5.3K	—
Jun 3, 2026	Chambers RebeccaChief Financial Officer	Sale at price 49.28 - 50.09 per share.	3.6K	$177.08K
Jun 3, 2026	Mcguire AnnieGeneral Counsel	Sale at price 49.31 - 50.12 per share.	3.2K	$158.04K
Jun 3, 2026	Leite JohnOfficer	Sale at price 50.07 per share.	14K	$699.73K
Jun 3, 2026	Stapley Marc AChief Executive Officer	Sale at price 50.12 per share.	138.1K	$6.92M
Jun 3, 2026	Stapley Marc AChief Executive Officer	Conversion of Exercise of derivative security at price 36.60 per share.	138.1K	$5.05M

CONG

Congress Trades · VCYT

House and Senate reports since 2025

Members

1 last bought

Buys

~$16.0K

Sells

~$8.0K

Net

+$8.0K

est. bought − sold

Latest

Mar 3, 26

Gilbert Cisneros

Members who traded it

Member	Buys	Sells	Est. net	Last move
Gilbert Cisneros CA31	2	1	+$8.0K	Bought Mar 3, 26

Bought and sold by quarter (est.)

Members of Congress's VCYT trades, newest first
Traded	Member	Owner	Type	Amount	Filed	Report
Mar 3, 26	Gilbert Cisneros CA31	Self	Buy	$1,001 - $15,000	Apr 7, 26 (35d)	PDF
Nov 12, 25	Gilbert Cisneros CA31	Self	Sell (part)	$1,001 - $15,000	Dec 15, 25 (33d)	PDF
Jun 16, 25	Gilbert Cisneros CA31	Self	Buy	$1,001 - $15,000	Jul 10, 25 (24d)	PDF

From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades

13F

Investors Holding VCYT

latest 13F filings of 29 followed managers

Investors holding VCYT
Investor	Value	Of portfolio	Shares	Change	Quarter
ARK Investment Management · Cathie Wood	$134.8M	0.88%	2.30M	−25%	Q2 2026
Bridgewater Associates · Ray Dalio	$3.4M	0.01%	58.29K	−36%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

VCYT

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

VCYT

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Veracyte, Inc.

Seasonality · VCYT

Insider Activity · VCYT

Congress Trades · VCYT

Members who traded it

Bought and sold by quarter (est.)

Investors Holding VCYT

Investors Holding VCYT

Congress Trades · VCYT

Members who traded it

Bought and sold by quarter (est.)

Insider Activity · VCYT

Seasonality · VCYT

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Veracyte, Inc.

Financial Snapshot

Earnings & Dividends

News